Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

This study has been completed.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: November 9, 2011
Last updated: March 10, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2015
  Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: March 10, 2015